Genetic Risk Factors for Gastrointestinal Stromal Tumors (GIST)
- To examine polymorphisms in selected genes involved in the detoxifying/metabolizing and
DNA repair pathways in relation to specific mutations and types of mutation in the
c-kit gene in tumor tissue from patients with gastrointestinal tumors (GIST) undergoing
treatment on clinical trial ACOSOG-Z9001.
- To examine approximately 758 polymorphisms among candidate genes involved in
detoxification/metabolism, cell cycle control, and DNA damage/repair in relation to
specific mutations and types of mutation in the c-kit gene in tumor tissue from GIST
patients for hypothesis generation. (exploratory)
- To conduct an exploratory analysis of the polymorphism distribution in these patients.
- To examine the association between the above polymorphisms and major toxicity (Grade
3/4) of adjuvant imatinib mesylate. (exploratory)
OUTLINE: Tumor samples are used for polymorphism and mutation analysis.
Polymorphisms in selected genes in relation to specific mutations and types of mutation in the c-kit gene
Memorial Sloan-Kettering Cancer Center
United States: Federal Government